Sentry Investment Management LLC Cuts Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Sentry Investment Management LLC decreased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 9.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 560 shares of the biopharmaceutical company’s stock after selling 60 shares during the quarter. Sentry Investment Management LLC’s holdings in Regeneron Pharmaceuticals were worth $492,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Markel Corp grew its stake in shares of Regeneron Pharmaceuticals by 1.3% in the first quarter. Markel Corp now owns 80,300 shares of the biopharmaceutical company’s stock worth $56,083,000 after acquiring an additional 1,000 shares in the last quarter. Cibc World Market Inc. grew its stake in shares of Regeneron Pharmaceuticals by 1.4% during the first quarter. Cibc World Market Inc. now owns 6,416 shares of the biopharmaceutical company’s stock worth $4,481,000 after purchasing an additional 86 shares in the last quarter. Blair William & Co. IL grew its stake in shares of Regeneron Pharmaceuticals by 18.4% during the first quarter. Blair William & Co. IL now owns 1,431 shares of the biopharmaceutical company’s stock worth $999,000 after purchasing an additional 222 shares in the last quarter. Sequoia Financial Advisors LLC grew its stake in shares of Regeneron Pharmaceuticals by 23.1% during the first quarter. Sequoia Financial Advisors LLC now owns 495 shares of the biopharmaceutical company’s stock worth $346,000 after purchasing an additional 93 shares in the last quarter. Finally, Baird Financial Group Inc. grew its stake in shares of Regeneron Pharmaceuticals by 100.9% during the first quarter. Baird Financial Group Inc. now owns 36,529 shares of the biopharmaceutical company’s stock worth $25,513,000 after purchasing an additional 18,345 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Insider Activity at Regeneron Pharmaceuticals

In related news, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $954.22, for a total value of $95,422.00. Following the completion of the sale, the director now owns 18,382 shares in the company, valued at $17,540,472.04. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In related news, Director Bonnie L. Bassler sold 854 shares of the firm’s stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $979.25, for a total value of $836,279.50. Following the completion of the sale, the director now owns 1,382 shares in the company, valued at $1,353,323.50. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $954.22, for a total transaction of $95,422.00. Following the completion of the sale, the director now owns 18,382 shares of the company’s stock, valued at approximately $17,540,472.04. The disclosure for this sale can be found here. Insiders sold a total of 13,729 shares of company stock worth $13,124,641 over the last 90 days. Company insiders own 8.83% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ:REGN opened at $898.56 on Tuesday. The company has a 50-day simple moving average of $956.81 and a 200-day simple moving average of $889.95. Regeneron Pharmaceuticals, Inc. has a one year low of $684.80 and a one year high of $998.33. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.94 and a current ratio of 5.69. The stock has a market capitalization of $98.63 billion, a price-to-earnings ratio of 25.86, a PEG ratio of 2.64 and a beta of 0.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 EPS for the quarter, beating analysts’ consensus estimates of $10.73 by $1.13. The business had revenue of $3.43 billion during the quarter, compared to analysts’ expectations of $3.29 billion. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. The business’s revenue was up .6% compared to the same quarter last year. During the same period in the prior year, the company earned $10.96 earnings per share. On average, analysts predict that Regeneron Pharmaceuticals, Inc. will post 38.18 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the stock. Barclays boosted their target price on shares of Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 23rd. Cantor Fitzgerald reiterated a “neutral” rating and set a $925.00 target price on shares of Regeneron Pharmaceuticals in a research note on Monday. Bank of America boosted their target price on shares of Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the stock an “underperform” rating in a research note on Friday. StockNews.com upgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday. Finally, Sanford C. Bernstein initiated coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, March 12th. They set an “outperform” rating and a $1,125.00 target price for the company. One analyst has rated the stock with a sell rating, four have issued a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $970.57.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.